Drug, Biotech Firms Beginning To Embrace Combinatorial Chemistry

Combinatorial Chemistry An emerging chemical discovery method is proving to be a fruitful source of research and job opportunities. The technique-called combinatorial chemistry-has spawned a wave of in-house pharmaceutical research and new collaboration between drug firms and biotech companies. Similar programs may also be on the horizon for agrochemical and materials science researchers. EUREKA: Ronald Zuckerman recalls Chiron's success Combinatorial chemistry shifts compound design from a

Written byKathryn Brown
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Combinatorial Chemistry An emerging chemical discovery method is proving to be a fruitful source of research and job opportunities. The technique-called combinatorial chemistry-has spawned a wave of in-house pharmaceutical research and new collaboration between drug firms and biotech companies. Similar programs may also be on the horizon for agrochemical and materials science researchers.


EUREKA: Ronald Zuckerman recalls Chiron's success
Combinatorial chemistry shifts compound design from a one-molecule-at-a-time approach to automated parallel synthesis. Starting with a useful compound or molecule, chemists can use robotics to spin that "lead" into thousands-or hundreds of thousands-of chemical variations. The resulting chemical diversity boosts the chance that a new compound will usefully react with a molecular target-say, a disease-causing molecule.

Drug and agrochemical industry leaders predict combinatorial chemistry will speed product discovery and open new doors for chemists. Pharmaceutical companies already are retraining and hiring chemists who can understand parallel processing, perform solid-state drug synthesis, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies